Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background: This study aims to assess the prognostic significance of serum lipoprotein (a) [Lp (a)] levels on overall survival (OS) and progression free survival (PFS) in individuals diagnosed with pancreatic cancer through the utilization of propensity score matching (PSM).
Methods: A retrospective analysis was conducted on the clinicopathological data of 364 patients diagnosed with pancreatic cancer at the Affiliated Hospital of Qingdao University from January 2019 to December 2022. The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups. We applied PSM analysis to minimize selection bias. The study compared OS and PFS between two groups by Kaplan-Meier method and analyzed differences using the log-rank test. Additionally, univariate and multivariate Cox-regression analyses were performed to identify prognostic factors among patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| the high Lp (a) groups and the low Lp (a) groups | The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups. |
| |
| the low Lp (a) groups | The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lp(a) | Other | The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups. |
|
| Measure | Description | Time Frame |
|---|---|---|
| OS | The primary endpoint was overall survival (OS), defined as the time from pathological diagnosis to either death or the most recent follow-up. | 1-30months |
| Measure | Description | Time Frame |
|---|---|---|
| PFS | The secondary measure was the duration from the initial diagnosis to disease progression, referred to as progression-free survival (PFS). Both are measured in months. | 1-10months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This research involved the inclusion of 364 individuals who were diagnosed with pancreatic cancer at the Affiliated Hospital of Qingdao University from January 2019 to December 2022, following pathological confirmation. The criteria for inclusion were as follows: (1) Adult patients aged over 18 years; (2) Patients with histologically confirmed pancreatic cancer through surgical or puncture procedures; (3) Complete lipid profiles available within one week prior to diagnosis. Exclusion criteria were as follows: (1) Presence of concurrent malignancies; (2) History of previous treatments such as pancreatectomy, chemotherapy, or radiation therapy; (3) Incomplete clinicopathological information.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jinyue liu | Contact | 17854269227 | liujinyue99@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Affiliated Hospital of Qingdao University | Recruiting | Qingdao | Shandong | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D001054 | Apolipoproteins A |
| ID | Term |
|---|---|
| D001053 | Apolipoproteins |
| D008074 | Lipoproteins |
| D008055 | Lipids |
| D001059 | Apoproteins |
| D011506 |
Not provided
Not provided
Not provided
Not provided
Not provided
| D004066 |
| Digestive System Diseases |
| D010182 | Pancreatic Diseases |
| D004700 | Endocrine System Diseases |
| Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |